Cargando…

The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout

The objective of the study was to evaluate the effect of lesinurad, a selective uric acid uptake inhibitor, alone and in combination with the xanthine oxidase inhibitor allopurinol, on serum uric acid and urinary urate excretion in patients with gout and hyperuricemia. A phase 1b, multicenter, open‐...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baumgartner, Scott, Yeh, Li‐Tain, Shen, Zancong, Kerr, Bradley, Manhard, Kimberly, Quart, Barry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099238/ https://www.ncbi.nlm.nih.gov/pubmed/29733441 http://dx.doi.org/10.1002/jcph.1124

Ejemplares similares

Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males
por: Shen, Zancong, et al.
Publicado: (2015)

Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
por: Miner, Jeffrey, et al.
Publicado: (2016)

Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
por: Miner, Jeffrey N., et al.
Publicado: (2016)

Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol
por: Perez-Ruiz, Fernando, et al.
Publicado: (2016)

In Vitro and In Vivo Interaction Studies Between Lesinurad, a Selective Urate Reabsorption Inhibitor, and Major Liver or Kidney Transporters
por: Shen, Zancong, et al.
Publicado: (2016)

Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers
por: Gillen, Michael, et al.
Publicado: (2016)

Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)
por: Bardin, Thomas, et al.
Publicado: (2017)

Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial
por: Dalbeth, Nicola, et al.
Publicado: (2017)

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout
por: Terkeltaub, Robert, et al.
Publicado: (2019)

Patient considerations in the management of gout and role of combination treatment with lesinurad
por: Claus, Liza W, et al.
Publicado: (2018)

Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout
por: Pérez-Ruiz, Fernando, et al.
Publicado: (2019)

Supratherapeutic dose evaluation and effect of lesinurad on cardiac repolarization: a thorough QT/QTc study
por: Shen, Zancong, et al.
Publicado: (2016)

Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study
por: Dalbeth, Nicola, et al.
Publicado: (2019)

Impact of Lesinurad and allopurinol on experimental Hyperuricemia in mice: biochemical, molecular and Immunohistochemical study
por: Alghamdi, Youssef Saeed, et al.
Publicado: (2020)

Guideline development for the management of gout: role of combination therapy with a focus on lesinurad
por: Jones, Graeme, et al.
Publicado: (2017)

Guideline development for the management of gout: role of combination therapy with a focus on lesinurad [Corrigendum]
Publicado: (2017)

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study
por: Fleischmann, Roy, et al.
Publicado: (2018)

Lesinurad: A significant advancement or just another addition to existing therapies of gout?
por: Gupta, Ajay, et al.
Publicado: (2016)

Synergic Effect of Allopurinol in Combination with Nitroheterocyclic Compounds against Trypanosoma cruzi
por: Mazzeti, Ana Lia, et al.
Publicado: (2019)

An Open‐Label Dose‐Finding Study of Allopurinol to Target Defined Reduction in Urate Levels in Hemodialysis Patients
por: Rutherford, Elaine, et al.
Publicado: (2017)

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout
por: Kankam, Martin, et al.
Publicado: (2018)

Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol
por: Dalbeth, Nicola, et al.
Publicado: (2018)

Diabetes and gout: efficacy and safety of febuxostat and allopurinol
por: Becker, M A, et al.
Publicado: (2013)

Hyperuricaemia, gout and allopurinol in the CKD Queensland registry
por: Jeyaruban, A., et al.
Publicado: (2021)

Factors Influencing Change in Serum Uric Acid After Administration of the Sodium‐Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus
por: Chino, Yukihiro, et al.
Publicado: (2021)

Lesinurad: what the nephrologist should know
por: Sanchez-Niño, Maria Dolores, et al.
Publicado: (2017)

Allopurinol, Benzbromarone, or a Combination in Treating Patients with Gout: Analysis of a Series of Outpatients
por: Azevedo, Valderilio Feijó, et al.
Publicado: (2014)

Discovery of URAT1 SNPs and association between serum uric acid levels and URAT1
por: Cho, Sung Kweon, et al.
Publicado: (2015)

Reassessing the Safety Profile of Lesinurad in Combination with Xanthine Oxidase Inhibitor Therapy
por: Perez-Ruiz, Fernando, et al.
Publicado: (2019)

Gout, flares, and allopurinol use: a population-based study
por: Proudman, Charlotte, et al.
Publicado: (2019)

Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout
por: Kang, Eun Ha, et al.
Publicado: (2021)

Cardiovascular risk associated with allopurinol or benzbromarone treatment in patients with gout
por: Eun, Yeonghee, et al.
Publicado: (2022)

Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease
por: Peng, Yueh-Lung, et al.
Publicado: (2020)

Factors Influencing the Serum Uric Acid in Gout with Cerebral Infarction
por: Li, Yi, et al.
Publicado: (2021)

Uric Acid Accumulation in Gout
Publicado: (1903)

Ultra-performance hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry for simultaneous determination of allopurinol, oxypurinol and lesinurad in rat plasma: Application to pharmacokinetic study in rats
por: Iqbal, Muzaffar, et al.
Publicado: (2019)

African American patients with gout: efficacy and safety of febuxostat vs allopurinol
por: Wells, Alvin F, et al.
Publicado: (2012)

Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes
por: Singh, Jasvinder A., et al.
Publicado: (2017)

Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout
por: Ali, Zakir, et al.
Publicado: (2022)

Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
por: Guan, Xudong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o7pq1s6kj57o02e9tlvnmu3g4r